Lopez-Campos JL, Calero C, Quintana-Gallego E. Symptom variability in COPD: a narrative review. Int J Chronic Obstruct Pulmon Dis. 2013;8:231–8.
Article
Google Scholar
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2019. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Cited 15 June 2020.
Lavorini F, Janson C, Braido F, Stratelis G, Løkke A. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532.
Article
Google Scholar
Miravitlles M, Soler-Cataluña JJ, Alcázar B, Viejo JL, García-Río F. Factors affecting the selection of an inhaler device for COPD and the ideal device for different patient profiles. Results of EPOCA Delphi consensus. Pulmon Pharmacol Ther. 2018;48:97–103.
CAS
Article
Google Scholar
van der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with two dry powder inhalers in patients with COPD. Expert Opin Drug Deliv. 2013;10(8):1023–31.
Article
Google Scholar
Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19(1):10.
Article
Google Scholar
Duarte-de-Araujo A, Teixeira P, Hespanhol V, Correia-de-Sousa J. COPD: analysing factors associated with a successful treatment. Pulmonology. 2020;26(2):66–72.
CAS
Article
Google Scholar
Sanduzzi A, Balbo P, Candoli P, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9(1):60.
Article
Google Scholar
Ghosh S, Pleasants RA, Ohar JA, Donohue JF, Drummond MB. Prevalence and factors associated with suboptimal peak inspiratory flow rates in COPD. Int J Chronic Obstruct Pulmon Dis. 2019;14:585–95.
CAS
Article
Google Scholar
Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chronic Obstruct Pulmon Dis. 2006;1(3):251–9.
CAS
Google Scholar
Dhand R, Eicher J, Hansel M, Jost I, Meisenheimer M, Wachtel H. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chronic Obstruct Pulmon Dis. 2019;14:509–23.
CAS
Article
Google Scholar
Dalby RN, Eicher J, Zierenberg B. Development of Respimat® Soft Mist Inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl, NZ). 2011;4:145–55.
CAS
Google Scholar
Sorino C, Negri S, Spanevello A, Visca D, Scichilone N. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15–8.
CAS
Article
Google Scholar
Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–24.
CAS
Article
Google Scholar
O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23(6):832–40.
CAS
Article
Google Scholar
Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur Respir J. 2015;45(4):969–79.
Article
Google Scholar
Ferguson GT, Karpel J, Bennett N, et al. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. NPJ Prim Care Respir Med. 2017;27(1):7.
Article
Google Scholar
Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of COPD: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69.
Article
Google Scholar
National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. https://www.nice.org.uk/guidance/ng115/chapter/Recommendations#ftn.footnote_3. Cited 15 June 2020.
Valipour A, Tamm M, Kociánová J, et al. Improvement of self-reported physical functioning with tiotropium/olodaterol in Central and Eastern European COPD patients. Int J Chronic Obstruct Pulmon Dis. 2019;14:2343–54.
Article
Google Scholar
Steinmetz KO, Abenhardt B, Pabst S, et al. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat® in patients with COPD in a real-world clinical setting. Int J Chronic Obstruct Pulmon Dis. 2019;14:1441–533.
CAS
Article
Google Scholar
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2017. https://goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. Cited 15 June 2020.
López-Campos JL, Quintana Gallego E, Carrasco HL. Status of and strategies for improving adherence to COPD treatment. Int J Chronic Obstruct Pulmon Dis. 2019;14:1503–15.
Article
Google Scholar
Khurana AK, Dubey K, Goyal A, Pawar KS, Phulwaria C, Pakhare A. Correcting inhaler technique decreases severity of obstruction and improves quality of life among patients with obstructive airway disease. J Fam Med Prim Care. 2019;8(1):246–50.
Article
Google Scholar
Pothirat C, Chaiwong W, Phetsuk N, Pisalthanapuna S, Chetsadaphan N, Choomuang W. Evaluating inhaler use technique in COPD patients. Int J Chronic Obstruct Pulmon Dis. 2015;10:1291–8.
CAS
Article
Google Scholar
Duarte-de-Araujo A, Teixeira P, Hespanhol V, Correia-de-Sousa J. COPD: misuse of inhaler devices in clinical practice. Int J Chronic Obstruct Pulmon Dis. 2019;14:1209–17.
CAS
Article
Google Scholar
Miravitlles M, Montero-Caballero J, Richard F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J Chronic Obstruct Pulmon Dis. 2016;11:407–15.
CAS
Article
Google Scholar
Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients' satisfaction with their inhalers on treatment compliance and health status in COPD. Respir Med. 2014;108(2):358–65.
Article
Google Scholar
Navaie M, Dembek C, Cho-Reyes S, Yeh K, Celli BR. Device use errors with soft mist inhalers: a global systematic literature review and meta-analysis. Chronic Respir Dis. 2020;17:1479973119901234.
Article
Google Scholar
Wachtel H, Kattenbeck S, Dunne S, Disse B. The Respimat® development story: patient-centered innovation. Pulmon Ther. 2017;3:19–30.
Article
Google Scholar
Hänsel M, Bambach T, Wachtel H. Reduced environmental impact of the reusable Respimat® Soft Mist™ inhaler compared with pressurised metered-dose inhalers. Adv Ther. 2019;36(9):2487–92.
Article
Google Scholar
Forster A, Sauer R, Mattiucci-Gühlke M, Berneburg J. Assessment of patient satisfaction and preference with the Respimat®. Pneumologie. 2020;74(S 01):P537.
Google Scholar
Schurmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction. Treat Respir Med. 2005;4(1):53–61.
Article
Google Scholar